ReviewPediatric blood & cancer2015
Going back to class I: MHC and immunotherapies for childhood cancer.
Review in Pediatric blood & cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 84 citations in OpenAlex.
- High expression of HLA-DQA1 predicts poor outcome in patients with esophageal squamous cell carcinoma in Northern China.Medicine · 2019Trial
- Irinotecan Modulates Immune Checkpoints in Neuroblastoma.ImmunoTargets and therapy · 2026Article
- CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy.Frontiers in immunology · 2026Article
- Overcoming barriers in primary bone cancer: Nanomaterial-enabled immunotherapy.Materials today. Bio · 2025Review
- Article
- Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.Blood neoplasia · 2025Article
- Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.British journal of cancer · 2024Article
- What role does GPR65 play in the progression of osteosarcoma? Its mechanism and clinical significance.Cancer cell international · 2024Article
- Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.European journal of cancer (Oxford, England : 1990) · 2023Review
- Epigenetic therapies for neuroblastoma: immunogenicity awakens.Molecular oncology · 2023Article
- The interaction between osteosarcoma and other cells in the bone microenvironment: From mechanism to clinical applications.Frontiers in cell and developmental biology · 2023Review
- Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and commonFrontiers in immunology · 2023Article
- Non-cellular immunotherapies in pediatric central nervous system tumors.Frontiers in immunology · 2023Review
- Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma.Cancers · 2022Review
- Stemness Correlates Inversely with MHC Class I Expression in Pediatric Small Round Blue Cell Tumors.Cancers · 2022Article
- Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.Nature medicine · 2022Observational
- DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma.PLoS computational biology · 2021Article
- Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.Cancers · 2021Review
- The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses.Immunity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.